ImmunityBio, Inc. Common Stock
IBRX Real Time Price USDRecent trades of IBRX by members of U.S. Congress
| Politician | Type | Traded |
|---|---|---|
| Daniel S. Goldman House / D | Sale $1,001 - $15,000 | Mar 06, 2023 |
---
|
Name
|
Type
|
Shares
|
Price
|
Shares Held
|
Date
|
Reported
|
|---|
|
Investor
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
|
Investor
|
Type
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
Recently reported changes in IBRX holdings by institutional investors
Quarterly net insider trading by IBRX's directors and management
* Insider trading data parsed from SEC Form 4 filings by Quiver Quantitative. Sign up for the Quiver API for real-time access.
- 1M
- 3M
- 6M
- YTD
- 1Y
- 2Y
- 5Y
- MAX
About
Key Metrics
Return (1d)
Return (30d)
Return (1Y)
CAGR (Total)
Max Drawdown
Beta
Alpha
Sharpe Ratio
Win Rate
Average Win
Average Loss
Annual Volatility
Annual Std Dev
Information Ratio
Treynor Ratio
Total Trades
Metrics Definitions
Disclaimer: The performance results shown are based on historical backtesting and are hypothetical in nature. Backtested performance does not represent actual trading and does not account for all market factors that may affect execution, such as liquidity, slippage, and changing market conditions. Past performance is not necessarily indicative of future results. There is no guarantee that any trading strategy will be profitable or avoid losses.
-
Alpha
Measures a portfolio's risk-adjusted performance against that of its benchmark
Learn More about Alpha -
Annual Standard Deviation
Measures how much the portfolio's total return varies from its mean or average.
Learn More about Annual Standard Deviation -
Annual Volatility
A statistical measure of the dispersion of returns for the portfolio.
Learn More about Annual Volatility -
Average Win
The average return (%) for trades that resulted in a positive return.
-
Average Loss
The average return (%) for trades that resulted in a negative return.
-
Beta
A measure of the volatility of the portfolio compared to the market as a whole.
Learn More about Beta -
CAGR
CAGR (Compounded Annual Growth Rate), is the historical annualized rate of return for an investment strategy, throughout the backtest period.
Learn More about CAGR -
Information Ratio
A measurement of portfolio returns beyond the returns of its benchmark compared to the volatility of those returns.
Learn More about Information Ratio -
Max Drawdown
the maximum observed loss from a peak to a trough of a portfolio, before a new peak is attained.
Learn More about Max Drawdown -
Sharpe Ratio
The Sharpe Ratio is a measure of historical risk-adjusted return, which quantifies the amount of return that an investor received per unit of risk.
Learn More about Sharpe Ratio -
Total Trades
The total number of trades made by this strategy.
-
Treynor Ratio
Attempts to measure how successful an investment is in providing compensation to investors for taking on investment risk.
Learn More about Treynor Ratio -
Win Rate
The percentage of total trades that resulted in a positive return.
Be the first to see our newest insights and key updates across all datasets.
Government lobbying spending instances
-
$60,000 Apr 18, 2026 Issue: None
-
$60,000 Jan 19, 2026 Issue: Health Issues
-
$45,000 Oct 08, 2022 Issue: Health Issues Medical/Disease Research/Clinical Labs
-
$45,000 Jul 19, 2022 Issue: Health Issues Medical/Disease Research/Clinical Labs
-
$60,000 Apr 09, 2022 Issue: Medical/Disease Research/Clinical Labs Health Issues
-
$60,000 Jan 17, 2022 Issue: Health Issues Medical/Disease Research/Clinical Labs
Former government officials who have lobbied for IBRX
2 former government officials from 1 congressional office at 2 lobbying firms have lobbied for IBRX, most recently Jan 19, 2026.
-
Timothy Costa Congress Chief of Staff to Dan Meuser
-
Megan Perez Burke House Legislative Director, Congresswoman Cathy McMorris Rodgers
IBRX Estimated quarterly lobbying spending
IBRX Revenue by Segment or Geography
New IBRX patent grants
-
Patent Title: Distributed ledger for medicament administration tracking Aug. 18, 2026
-
Patent Title: Multi-chain chimeric polypeptides and uses thereof Jul. 28, 2026
-
Patent Title: Compositions and methods for nk-92 cells expressing native cd16 Jul. 14, 2026
-
Patent Title: Nant cancer vaccine Jun. 16, 2026
-
Patent Title: Methods of reducing neuroinflammation Apr. 07, 2026
-
Patent Title: Quadricistronic system comprising a homing receptor and chimeric antigen receptor for stable genetic modification of cellular immunotherapies Mar. 24, 2026
-
Patent Title: Intratumorally injected yeast vaccine Feb. 24, 2026
-
Patent Title: Single-chain chimeric polypeptides and uses thereof Jan. 06, 2026
-
Patent Title: Recombinant eril-15 nk cells Jan. 06, 2026
-
Patent Title: Multi-chain chimeric polypeptides and uses thereof Dec. 30, 2025
-
Patent Title: Combined invasion and cytotoxicity assay using chemokine secreting target cells Dec. 16, 2025
-
Patent Title: Anti-cd26 proteins and uses thereof Dec. 16, 2025
-
Patent Title: Modified nk-92 hank003 cells for the clinic Dec. 09, 2025
-
Patent Title: Maximizing t-cell memory and compositions and methods therefor Dec. 09, 2025
-
Patent Title: Multi-chain chimeric polypeptides and uses thereof Nov. 25, 2025
-
Patent Title: Elimination of pd-l1-positive malignancies by pd-l1 chimeric antigen receptor-expressing nk cells Nov. 18, 2025
-
Patent Title: Elimination of pd-l1-positive malignancies by pd-l1 chimeric antigen receptor-expressing nk cells Nov. 18, 2025
-
Patent Title: Primary nk car constructs and methods Nov. 04, 2025
-
Patent Title: Fiducial localization with sparse annotations Oct. 28, 2025
-
Patent Title: Enzyme based system for production of messenger rna with increased transfection efficiency Oct. 21, 2025
-
Patent Title: Fc-epsilon car Oct. 07, 2025
-
Patent Title: Neoepitope vaccine delivery vehicle and methods of making the same Sep. 09, 2025
-
Patent Title: Use of cd33car modified high affinity nk cells (t-hank) to reduce myeloid-derived suppressor cells suppressor activity (or reduce negative impact on nk cell activity) Sep. 02, 2025
-
Patent Title: Multi-chain chimeric polypeptides and uses thereof Aug. 26, 2025
-
Patent Title: Elimination of cd19-positive lymphoid malignancies by cd19-car expressing nk cells Aug. 05, 2025
-
Patent Title: Chimeric antigen receptor-modified nk-92 cells targeting egfr super-family receptors Jul. 22, 2025
-
Patent Title: Sars-cov-2 vaccines comprising human adenovirus vectors encoding spike and nucleocapsid-etsd immunogens May. 06, 2025
-
Patent Title: Adenoviral vector transduced apheresis product Apr. 15, 2025
-
Patent Title: Distributed ledger for medicament administration tracking Apr. 08, 2025
-
Patent Title: Multi-chain chimeric polypeptides and uses thereof Apr. 08, 2025
-
Patent Title: Mononuclear cell derived nk cells Feb. 04, 2025
-
Patent Title: Advanced avatar dendritic cells Jan. 14, 2025
-
Patent Title: Chromatography resin and uses thereof Jan. 07, 2025
-
Patent Title: Methods and systems for producing a protein of interest in a plant Dec. 31, 2024
-
Patent Title: Nant covid vaccine cross reactivity Dec. 17, 2024
-
Patent Title: Methods of treating age-related and inflammatory diseases Oct. 15, 2024
-
Patent Title: Chimeric antigen receptor-modified nk-92 cells Oct. 08, 2024
-
Patent Title: Biological deposit labeling and tracking including isotope, rare earth metal or mitochondria tags Sep. 10, 2024
-
Patent Title: Tumoricidal and antimicrobial compositions and methods Aug. 20, 2024
-
Patent Title: Advanced avatar dendritic cells Jul. 23, 2024
-
Patent Title: Nant covid vaccine cross reactivity Jun. 25, 2024
-
Patent Title: Cell-mediated transient delivery of immune-enhancing molecules into the tumor microenvironment May. 28, 2024
-
Patent Title: Tumoricidal and antimicrobial compositions and methods May. 07, 2024
-
Patent Title: Generating cik nkt cells from cord blood Mar. 19, 2024
-
Patent Title: Method of inducing immunity against sars-cov-2 using spike (s) and nucleocapsid (n)-etsd immunogens delivered by a replication-defective adenovirus Jan. 02, 2024
-
Patent Title: Modified nk-92 hank003 cells for the clinic Sep. 12, 2023
-
Patent Title: Fc-epsilon car May. 09, 2023
-
Patent Title: Chimeric antigen receptor-modified nk-92 cells Jan. 10, 2023
-
Patent Title: Mononuclear cell derived nk cells Sep. 27, 2022
-
Patent Title: Generating cik nkt cells from cord blood Jun. 07, 2022
Federal grants, loans, and purchases
Estimated quarterly amount awarded to IBRX from public contracts
Recent insights relating to IBRX
Recent picks made for IBRX stock on CNBC
ETFs with the largest estimated holdings in IBRX
- ... Highest Price Target
- ... Median Price Target
- ... Lowest Price Target
|
Analyst
|
Firm
|
Current
|
Previous
|
Date
|
|---|
- Is $IBRX stock a Buy, Sell, or Hold?
- What is the price target for $IBRX stock?
* Analyst consensus is not financial advice. Please see our data disclaimers .
|
Shareholder
|
Shares Held
|
|---|
- Who owns $IBRX stock?
- Who owns the most shares of $IBRX stock?
- What funds own $IBRX stock?
* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.Sign Up to view IBRX Smart Score
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
The Bulls Say summary highlights positive aspects of the stock.
The Bears Say summary points out potential risks and negative aspects of the stock.
ImmunityBio Inc is a biotechnology company focused on developing and commercializing next-generation immunotherapies designed to activate the patient's immune system and provide durable protection against cancer and infectious diseases. Its approach harnesses both the adaptive and innate immune systems with the Cancer BioShield platform. The platform is built around the proprietary IL-15 superagonist ANKTIVA (nogapendekin alfa inbakicept) and is supported by a portfolio that includes adenovirus-vectored vaccines, NK-cell therapies, and additional immunomodulators. The company operates in the United States and Europe, with the majority of its revenue coming from the United States.
- Address San Diego, CA
- Market Cap 9.8 billion
- Employees 691
- Industrial Classification Biological Products, (No Diagnostic Substances)
ImmunityBio, Inc. Common Stock (IBRX) Historical Stock Prices
ImmunityBio, Inc. Common Stock (IBRX) closed at $9.29 on September 22, 2026. Over the past year its adjusted close ranged from $1.98 to $11.55. Daily prices go back to July 28, 2015, 2,805 trading days in all.
- 1 month+19.26%
- 3 months+26.91%
- Year to date+369.19%
- 1 year+247.94%
- 3 years+463.03%
- 5 years-13.26%
- Max-73.18%
Quiver Premium charts IBRX's full daily history since 2014 with each congressional purchase and sale and every open-market insider purchase marked on the price line, with hover details for each trade.
Upgrade to Premium| Date | Open | High | Low | Close | Adj. Close | Volume |
|---|---|---|---|---|---|---|
| Sep 22, 2026 | 8.45 | 9.48 | 8.37 | 9.29 | 9.29 | 21,133,175 |
| Sep 21, 2026 | 8.72 | 8.87 | 8.26 | 8.45 | 8.45 | 12,238,176 |
| Sep 18, 2026 | 8.46 | 8.53 | 8.20 | 8.48 | 8.48 | 18,428,898 |
| Sep 17, 2026 | 8.14 | 8.80 | 8.12 | 8.46 | 8.46 | 19,159,326 |
| Sep 16, 2026 | 8.13 | 8.30 | 7.76 | 7.91 | 7.91 | 9,204,975 |
| Sep 15, 2026 | 8.32 | 8.34 | 7.85 | 8.14 | 8.14 | 8,949,305 |
| Sep 14, 2026 | 7.89 | 8.40 | 7.87 | 8.37 | 8.37 | 9,158,261 |
| Sep 11, 2026 | 7.80 | 8.35 | 7.80 | 7.91 | 7.91 | 12,468,768 |
| Sep 10, 2026 | 7.87 | 7.89 | 7.64 | 7.72 | 7.72 | 8,805,734 |
| Sep 9, 2026 | 8.22 | 8.36 | 7.88 | 8.06 | 8.06 | 9,488,937 |
| Sep 8, 2026 | 8.00 | 8.37 | 7.93 | 8.29 | 8.29 | 7,741,308 |
| Sep 4, 2026 | 8.08 | 8.24 | 8.01 | 8.08 | 8.08 | 4,330,218 |
| Sep 3, 2026 | 8.00 | 8.21 | 7.88 | 8.19 | 8.19 | 5,271,763 |
| Sep 2, 2026 | 7.95 | 8.28 | 7.75 | 7.95 | 7.95 | 7,228,321 |
| Sep 1, 2026 | 7.82 | 7.99 | 7.73 | 7.87 | 7.87 | 6,465,675 |
| Aug 31, 2026 | 7.88 | 8.02 | 7.84 | 7.95 | 7.95 | 6,881,639 |
| Aug 28, 2026 | 8.31 | 8.32 | 7.95 | 8.05 | 8.05 | 7,980,048 |
| Aug 27, 2026 | 8.24 | 8.76 | 8.18 | 8.40 | 8.40 | 12,311,454 |
| Aug 26, 2026 | 8.17 | 8.40 | 8.07 | 8.25 | 8.25 | 9,446,459 |
| Aug 25, 2026 | 7.69 | 8.23 | 7.68 | 8.19 | 8.19 | 11,547,392 |
| Aug 24, 2026 | 7.68 | 7.72 | 7.46 | 7.58 | 7.58 | 5,671,527 |
| Aug 21, 2026 | 7.85 | 7.95 | 7.60 | 7.79 | 7.79 | 7,619,706 |
| Aug 20, 2026 | 7.90 | 8.00 | 7.74 | 7.84 | 7.84 | 8,099,182 |
| Aug 19, 2026 | 8.08 | 8.27 | 7.94 | 8.13 | 8.13 | 13,063,682 |
| Aug 18, 2026 | 7.79 | 7.83 | 7.54 | 7.72 | 7.72 | 5,413,300 |
| Aug 17, 2026 | 7.55 | 7.95 | 7.44 | 7.92 | 7.92 | 6,816,455 |
| Aug 14, 2026 | 7.59 | 7.59 | 7.43 | 7.57 | 7.57 | 4,912,668 |
| Aug 13, 2026 | 7.80 | 7.96 | 7.59 | 7.65 | 7.65 | 6,006,747 |
| Aug 12, 2026 | 7.71 | 7.82 | 7.60 | 7.74 | 7.74 | 5,340,411 |
| Aug 11, 2026 | 7.54 | 7.66 | 7.48 | 7.60 | 7.60 | 5,033,049 |
| Aug 10, 2026 | 7.51 | 7.70 | 7.42 | 7.49 | 7.49 | 6,001,570 |
| Aug 7, 2026 | 7.40 | 7.65 | 7.25 | 7.64 | 7.64 | 9,391,476 |
| Aug 6, 2026 | 7.24 | 7.49 | 7.18 | 7.32 | 7.32 | 7,786,658 |
| Aug 5, 2026 | 6.96 | 7.41 | 6.94 | 7.25 | 7.25 | 11,508,346 |
| Aug 4, 2026 | 6.76 | 7.26 | 6.70 | 6.95 | 6.95 | 19,006,776 |
| Aug 3, 2026 | 7.18 | 7.42 | 7.10 | 7.15 | 7.15 | 8,755,817 |
| Jul 31, 2026 | 7.45 | 7.62 | 7.10 | 7.17 | 7.17 | 9,366,047 |
| Jul 30, 2026 | 7.22 | 7.47 | 7.00 | 7.45 | 7.45 | 11,162,019 |
| Jul 29, 2026 | 6.98 | 7.13 | 6.74 | 6.83 | 6.83 | 8,723,319 |
| Jul 28, 2026 | 6.93 | 6.99 | 6.65 | 6.97 | 6.97 | 11,882,140 |
| Jul 27, 2026 | 7.25 | 7.37 | 6.90 | 6.99 | 6.99 | 10,517,948 |
| Jul 24, 2026 | 7.40 | 7.45 | 7.06 | 7.10 | 7.10 | 8,524,632 |
| Jul 23, 2026 | 7.36 | 7.57 | 7.33 | 7.40 | 7.40 | 6,132,647 |
| Jul 22, 2026 | 7.95 | 8.10 | 7.50 | 7.51 | 7.51 | 8,880,733 |
| Jul 21, 2026 | 7.58 | 8.14 | 7.54 | 8.07 | 8.07 | 8,623,911 |
| Jul 20, 2026 | 7.66 | 7.79 | 7.43 | 7.50 | 7.50 | 7,238,607 |
| Jul 17, 2026 | 7.28 | 7.79 | 7.26 | 7.68 | 7.68 | 9,025,459 |
| Jul 16, 2026 | 7.61 | 7.66 | 7.33 | 7.45 | 7.45 | 7,706,336 |
| Jul 15, 2026 | 7.75 | 7.87 | 7.56 | 7.73 | 7.73 | 6,702,000 |
| Jul 14, 2026 | 7.83 | 7.99 | 7.65 | 7.88 | 7.88 | 7,466,371 |
| Jul 13, 2026 | 8.05 | 8.16 | 7.73 | 7.79 | 7.79 | 9,894,898 |
| Jul 10, 2026 | 8.92 | 8.92 | 8.05 | 8.22 | 8.22 | 12,862,137 |
| Jul 9, 2026 | 8.78 | 9.09 | 8.63 | 8.87 | 8.87 | 11,355,717 |
| Jul 8, 2026 | 8.72 | 9.21 | 8.61 | 8.80 | 8.80 | 9,756,607 |
| Jul 7, 2026 | 8.96 | 9.01 | 8.34 | 8.76 | 8.76 | 11,232,609 |
| Jul 6, 2026 | 9.30 | 9.53 | 8.63 | 8.91 | 8.91 | 13,475,977 |
| Jul 2, 2026 | 9.23 | 9.60 | 9.03 | 9.44 | 9.44 | 14,674,825 |
| Jul 1, 2026 | 8.64 | 9.34 | 8.51 | 9.20 | 9.20 | 16,451,724 |
| Jun 30, 2026 | 8.80 | 9.00 | 8.56 | 8.76 | 8.76 | 9,299,169 |
| Jun 29, 2026 | 8.36 | 9.08 | 8.33 | 8.77 | 8.77 | 15,768,466 |
| Jun 26, 2026 | 7.74 | 8.85 | 7.67 | 8.71 | 8.71 | 41,198,290 |
| Jun 25, 2026 | 7.70 | 7.89 | 7.51 | 7.79 | 7.79 | 9,425,105 |
| Jun 24, 2026 | 7.34 | 7.96 | 7.26 | 7.80 | 7.80 | 16,529,679 |
| Jun 23, 2026 | 7.05 | 7.60 | 7.00 | 7.32 | 7.32 | 11,316,360 |
| Jun 22, 2026 | 7.49 | 7.55 | 7.17 | 7.22 | 7.22 | 9,888,330 |
| Jun 18, 2026 | 7.15 | 7.46 | 7.03 | 7.36 | 7.36 | 14,372,395 |
| Jun 17, 2026 | 6.75 | 7.25 | 6.71 | 6.99 | 6.99 | 13,199,303 |
| Jun 16, 2026 | 7.12 | 7.21 | 6.68 | 6.72 | 6.72 | 12,797,590 |
| Jun 15, 2026 | 7.25 | 7.34 | 7.05 | 7.13 | 7.13 | 8,140,230 |
| Jun 12, 2026 | 7.24 | 7.32 | 7.04 | 7.10 | 7.10 | 8,816,047 |
| Jun 11, 2026 | 7.00 | 7.26 | 6.92 | 7.20 | 7.20 | 8,611,272 |
| Jun 10, 2026 | 7.16 | 7.41 | 6.98 | 6.98 | 6.98 | 9,421,149 |
| Jun 9, 2026 | 7.29 | 7.44 | 6.92 | 7.25 | 7.25 | 12,672,982 |
| Jun 8, 2026 | 7.12 | 7.31 | 6.97 | 7.17 | 7.17 | 11,386,995 |
| Jun 5, 2026 | 7.15 | 7.29 | 6.79 | 6.92 | 6.92 | 13,818,425 |
| Jun 4, 2026 | 7.21 | 7.47 | 7.12 | 7.29 | 7.29 | 9,612,074 |
| Jun 3, 2026 | 7.23 | 7.30 | 7.03 | 7.18 | 7.18 | 8,968,000 |
| Jun 2, 2026 | 7.24 | 7.28 | 7.02 | 7.23 | 7.23 | 13,723,361 |
| Jun 1, 2026 | 7.37 | 7.51 | 7.11 | 7.24 | 7.24 | 20,423,935 |
| May 29, 2026 | 7.65 | 7.65 | 7.23 | 7.52 | 7.52 | 15,617,375 |
| May 28, 2026 | 7.85 | 8.09 | 7.63 | 7.72 | 7.72 | 12,625,869 |
| May 27, 2026 | 7.89 | 8.29 | 7.79 | 7.89 | 7.89 | 14,532,401 |
| May 26, 2026 | 7.28 | 8.03 | 7.27 | 7.92 | 7.92 | 19,077,232 |
| May 22, 2026 | 7.62 | 7.69 | 7.15 | 7.22 | 7.22 | 17,939,227 |
| May 21, 2026 | 7.87 | 7.90 | 7.26 | 7.74 | 7.74 | 21,529,698 |
| May 20, 2026 | 8.42 | 8.64 | 8.04 | 8.05 | 8.05 | 24,815,743 |
| May 19, 2026 | 7.96 | 7.96 | 7.33 | 7.76 | 7.76 | 17,956,277 |
| May 18, 2026 | 8.34 | 8.53 | 7.74 | 8.00 | 8.00 | 13,084,842 |
| May 15, 2026 | 8.05 | 8.14 | 7.80 | 7.97 | 7.97 | 11,347,554 |
| May 14, 2026 | 8.24 | 8.42 | 7.92 | 8.15 | 8.15 | 9,402,569 |
| May 13, 2026 | 8.01 | 8.34 | 7.78 | 8.15 | 8.15 | 10,542,917 |
| May 12, 2026 | 7.97 | 8.21 | 7.85 | 8.12 | 8.12 | 9,900,490 |
| May 11, 2026 | 8.44 | 8.69 | 7.93 | 8.11 | 8.11 | 14,502,080 |
| May 8, 2026 | 7.88 | 8.56 | 7.58 | 8.51 | 8.51 | 16,203,766 |
| May 7, 2026 | 7.82 | 8.11 | 7.36 | 7.76 | 7.76 | 18,819,794 |
| May 6, 2026 | 7.70 | 8.39 | 7.67 | 8.38 | 8.38 | 19,637,832 |
| May 5, 2026 | 7.54 | 7.77 | 7.43 | 7.58 | 7.58 | 9,510,284 |
| May 4, 2026 | 7.11 | 7.62 | 7.05 | 7.43 | 7.43 | 11,850,213 |
| May 1, 2026 | 7.05 | 7.28 | 6.94 | 7.11 | 7.11 | 7,715,407 |
| Apr 30, 2026 | 6.99 | 7.18 | 6.95 | 7.10 | 7.10 | 6,536,515 |
| Apr 29, 2026 | 6.93 | 6.98 | 6.73 | 6.96 | 6.96 | 9,274,434 |
| Apr 28, 2026 | 7.25 | 7.27 | 6.91 | 6.96 | 6.96 | 10,876,044 |
| Apr 27, 2026 | 7.36 | 7.50 | 7.06 | 7.29 | 7.29 | 11,120,133 |
| Apr 24, 2026 | 8.16 | 8.28 | 7.41 | 7.44 | 7.44 | 16,939,878 |
| Apr 23, 2026 | 7.97 | 8.27 | 7.82 | 8.19 | 8.19 | 9,775,089 |
| Apr 22, 2026 | 8.27 | 8.38 | 7.75 | 8.07 | 8.07 | 11,414,438 |
| Apr 21, 2026 | 8.37 | 8.56 | 7.98 | 8.10 | 8.10 | 13,170,250 |
| Apr 20, 2026 | 7.66 | 8.35 | 7.65 | 8.20 | 8.20 | 16,211,232 |
| Apr 17, 2026 | 7.29 | 7.90 | 7.26 | 7.70 | 7.70 | 21,520,488 |
| Apr 16, 2026 | 7.77 | 7.85 | 7.12 | 7.25 | 7.25 | 17,552,938 |
| Apr 15, 2026 | 7.54 | 7.80 | 7.36 | 7.78 | 7.78 | 10,524,603 |
| Apr 14, 2026 | 7.33 | 7.82 | 7.33 | 7.60 | 7.60 | 15,645,827 |
| Apr 13, 2026 | 7.30 | 7.36 | 7.06 | 7.30 | 7.30 | 9,619,742 |
| Apr 10, 2026 | 7.35 | 7.55 | 7.10 | 7.28 | 7.28 | 14,361,221 |
| Apr 9, 2026 | 7.00 | 7.64 | 6.97 | 7.48 | 7.48 | 21,588,055 |
| Apr 8, 2026 | 7.30 | 7.42 | 6.80 | 6.98 | 6.98 | 16,541,531 |
| Apr 7, 2026 | 6.98 | 7.00 | 6.68 | 6.86 | 6.86 | 12,979,132 |
| Apr 6, 2026 | 7.27 | 7.63 | 6.99 | 7.08 | 7.08 | 13,321,775 |
| Apr 2, 2026 | 6.89 | 7.35 | 6.88 | 7.30 | 7.30 | 14,223,092 |
| Apr 1, 2026 | 7.55 | 7.85 | 7.01 | 7.14 | 7.14 | 19,422,073 |
| Mar 31, 2026 | 7.15 | 7.75 | 7.08 | 7.67 | 7.67 | 24,131,981 |
| Mar 30, 2026 | 7.22 | 7.27 | 6.57 | 6.66 | 6.66 | 24,496,983 |
| Mar 27, 2026 | 7.37 | 7.65 | 7.13 | 7.38 | 7.38 | 14,455,030 |
| Mar 26, 2026 | 7.90 | 8.43 | 7.22 | 7.38 | 7.38 | 27,582,987 |
| Mar 25, 2026 | 7.75 | 8.35 | 7.45 | 8.07 | 8.07 | 29,057,430 |
| Mar 24, 2026 | 9.07 | 9.15 | 6.54 | 7.42 | 7.42 | 86,945,591 |
| Mar 23, 2026 | 8.54 | 9.54 | 8.46 | 9.40 | 9.40 | 26,747,948 |
| Mar 20, 2026 | 8.94 | 9.32 | 8.40 | 8.47 | 8.47 | 31,639,947 |
| Mar 19, 2026 | 8.41 | 8.87 | 8.35 | 8.82 | 8.82 | 17,916,536 |
| Mar 18, 2026 | 8.08 | 8.92 | 8.05 | 8.56 | 8.56 | 22,457,360 |
| Mar 17, 2026 | 8.93 | 9.30 | 8.12 | 8.21 | 8.21 | 28,677,809 |
| Mar 16, 2026 | 8.52 | 8.67 | 8.02 | 8.21 | 8.21 | 16,884,436 |
| Mar 13, 2026 | 8.21 | 8.91 | 8.20 | 8.39 | 8.39 | 30,623,281 |
| Mar 12, 2026 | 8.13 | 8.23 | 7.81 | 7.82 | 7.82 | 14,715,775 |
| Mar 11, 2026 | 8.04 | 8.40 | 7.86 | 8.27 | 8.27 | 17,270,122 |
| Mar 10, 2026 | 8.22 | 8.34 | 7.77 | 8.01 | 8.01 | 24,405,209 |
| Mar 9, 2026 | 8.29 | 8.79 | 8.04 | 8.45 | 8.45 | 25,645,691 |
| Mar 6, 2026 | 8.78 | 9.12 | 8.49 | 8.67 | 8.67 | 23,018,213 |
| Mar 5, 2026 | 9.02 | 9.36 | 8.80 | 8.96 | 8.96 | 19,354,310 |
| Mar 4, 2026 | 9.45 | 9.60 | 8.93 | 9.00 | 9.00 | 33,213,155 |
| Mar 3, 2026 | 10.00 | 10.58 | 9.80 | 10.00 | 10.00 | 28,355,595 |
| Mar 2, 2026 | 9.64 | 10.98 | 9.63 | 10.44 | 10.44 | 41,106,666 |
| Feb 27, 2026 | 9.41 | 9.80 | 8.83 | 9.78 | 9.78 | 30,440,201 |
| Feb 26, 2026 | 9.91 | 9.97 | 8.98 | 9.55 | 9.55 | 37,880,583 |
| Feb 25, 2026 | 12.17 | 12.43 | 9.38 | 9.54 | 9.54 | 80,841,117 |
| Feb 24, 2026 | 10.15 | 12.28 | 9.95 | 11.55 | 11.55 | 83,228,842 |
| Feb 23, 2026 | 9.95 | 11.00 | 9.55 | 9.83 | 9.83 | 86,445,140 |
| Feb 20, 2026 | 8.63 | 9.25 | 8.32 | 8.70 | 8.70 | 45,429,249 |
| Feb 19, 2026 | 8.05 | 8.95 | 7.60 | 8.61 | 8.61 | 55,342,178 |
| Feb 18, 2026 | 6.06 | 8.68 | 6.06 | 8.54 | 8.54 | 80,016,255 |
| Feb 17, 2026 | 6.26 | 6.28 | 5.93 | 6.02 | 6.02 | 14,622,777 |
| Feb 13, 2026 | 6.62 | 7.30 | 5.94 | 5.95 | 5.95 | 39,435,965 |
| Feb 12, 2026 | 6.53 | 6.87 | 6.40 | 6.62 | 6.62 | 13,449,139 |
| Feb 11, 2026 | 6.72 | 6.77 | 6.28 | 6.54 | 6.54 | 17,178,983 |
| Feb 10, 2026 | 6.95 | 7.14 | 6.55 | 6.56 | 6.56 | 22,096,927 |
| Feb 9, 2026 | 6.05 | 7.03 | 5.82 | 6.93 | 6.93 | 24,292,281 |
| Feb 6, 2026 | 5.70 | 6.08 | 5.61 | 6.05 | 6.05 | 18,256,123 |
| Feb 5, 2026 | 5.72 | 5.98 | 5.58 | 5.64 | 5.64 | 18,450,636 |
| Feb 4, 2026 | 6.29 | 6.29 | 5.69 | 5.88 | 5.88 | 21,454,505 |
| Feb 3, 2026 | 6.14 | 6.54 | 5.95 | 6.33 | 6.33 | 21,175,106 |
| Feb 2, 2026 | 6.29 | 6.75 | 5.93 | 6.13 | 6.13 | 24,656,226 |
| Jan 30, 2026 | 5.78 | 6.46 | 5.67 | 6.25 | 6.25 | 29,537,843 |
| Jan 29, 2026 | 6.15 | 6.35 | 5.73 | 5.91 | 5.91 | 24,763,637 |
| Jan 28, 2026 | 6.01 | 6.29 | 5.54 | 6.15 | 6.15 | 35,336,363 |
| Jan 27, 2026 | 5.96 | 6.13 | 5.59 | 5.95 | 5.95 | 38,640,654 |
| Jan 26, 2026 | 6.66 | 6.75 | 6.16 | 6.21 | 6.21 | 37,937,209 |
| Jan 23, 2026 | 7.38 | 7.88 | 6.43 | 6.45 | 6.45 | 75,849,418 |
| Jan 22, 2026 | 7.45 | 8.28 | 6.90 | 7.34 | 7.34 | 81,256,998 |
| Jan 21, 2026 | 6.27 | 7.10 | 5.71 | 6.92 | 6.92 | 96,093,541 |
| Jan 20, 2026 | 6.54 | 7.98 | 6.08 | 6.48 | 6.48 | 211,045,135 |
| Jan 16, 2026 | 4.70 | 5.58 | 4.38 | 5.52 | 5.52 | 182,353,701 |
| Jan 15, 2026 | 3.14 | 3.99 | 3.07 | 3.95 | 3.95 | 76,069,692 |
| Jan 14, 2026 | 2.99 | 3.10 | 2.88 | 3.02 | 3.02 | 45,608,569 |
| Jan 13, 2026 | 2.68 | 2.92 | 2.62 | 2.82 | 2.82 | 32,785,281 |
| Jan 12, 2026 | 2.34 | 2.62 | 2.28 | 2.59 | 2.59 | 16,887,160 |
| Jan 9, 2026 | 2.26 | 2.43 | 2.26 | 2.33 | 2.33 | 12,508,552 |
| Jan 8, 2026 | 2.16 | 2.28 | 2.14 | 2.24 | 2.24 | 7,686,152 |
| Jan 7, 2026 | 2.16 | 2.25 | 2.14 | 2.20 | 2.20 | 10,052,829 |
| Jan 6, 2026 | 2.10 | 2.18 | 2.08 | 2.14 | 2.14 | 8,867,594 |
| Jan 5, 2026 | 2.05 | 2.10 | 2.03 | 2.08 | 2.08 | 9,788,505 |
| Jan 2, 2026 | 2.02 | 2.07 | 1.98 | 2.02 | 2.02 | 10,373,131 |
| Dec 31, 2025 | 1.98 | 2.00 | 1.95 | 1.98 | 1.98 | 9,885,436 |
| Dec 30, 2025 | 2.04 | 2.05 | 1.97 | 1.98 | 1.98 | 11,024,543 |
| Dec 29, 2025 | 2.12 | 2.14 | 2.03 | 2.04 | 2.04 | 12,086,886 |
| Dec 26, 2025 | 2.14 | 2.15 | 2.10 | 2.14 | 2.14 | 7,221,723 |
| Dec 24, 2025 | 2.12 | 2.15 | 2.09 | 2.14 | 2.14 | 5,408,762 |
| Dec 23, 2025 | 2.25 | 2.25 | 2.07 | 2.10 | 2.10 | 14,975,110 |
| Dec 22, 2025 | 2.12 | 2.29 | 2.11 | 2.27 | 2.27 | 14,048,224 |
| Dec 19, 2025 | 2.09 | 2.14 | 2.00 | 2.08 | 2.08 | 41,734,277 |
| Dec 18, 2025 | 2.13 | 2.13 | 2.07 | 2.09 | 2.09 | 12,255,686 |
| Dec 17, 2025 | 2.16 | 2.17 | 2.06 | 2.11 | 2.11 | 15,755,917 |
| Dec 16, 2025 | 2.19 | 2.25 | 2.14 | 2.16 | 2.16 | 16,737,810 |
| Dec 15, 2025 | 2.40 | 2.42 | 2.15 | 2.22 | 2.22 | 16,580,206 |
| Dec 12, 2025 | 2.29 | 2.50 | 2.25 | 2.36 | 2.36 | 24,855,981 |
| Dec 11, 2025 | 2.30 | 2.31 | 2.19 | 2.19 | 2.19 | 8,347,375 |
| Dec 10, 2025 | 2.23 | 2.30 | 2.17 | 2.30 | 2.30 | 11,120,052 |
| Dec 9, 2025 | 2.24 | 2.27 | 2.19 | 2.22 | 2.22 | 8,504,900 |
| Dec 8, 2025 | 2.31 | 2.40 | 2.25 | 2.26 | 2.26 | 10,359,356 |
| Dec 5, 2025 | 2.31 | 2.32 | 2.24 | 2.29 | 2.29 | 6,847,121 |
| Dec 4, 2025 | 2.20 | 2.34 | 2.16 | 2.30 | 2.30 | 12,027,325 |
| Dec 3, 2025 | 2.09 | 2.20 | 2.08 | 2.20 | 2.20 | 12,408,054 |
| Dec 2, 2025 | 2.33 | 2.33 | 2.06 | 2.09 | 2.09 | 16,508,324 |
| Dec 1, 2025 | 2.40 | 2.46 | 2.28 | 2.30 | 2.30 | 19,437,429 |
| Nov 28, 2025 | 2.29 | 2.45 | 2.25 | 2.36 | 2.36 | 21,337,605 |
| Nov 26, 2025 | 2.11 | 2.16 | 2.07 | 2.13 | 2.13 | 8,487,999 |
| Nov 25, 2025 | 2.18 | 2.18 | 2.05 | 2.08 | 2.08 | 7,280,945 |
| Nov 24, 2025 | 2.10 | 2.15 | 2.08 | 2.15 | 2.15 | 9,440,137 |
| Nov 21, 2025 | 2.03 | 2.15 | 2.01 | 2.08 | 2.08 | 9,945,248 |
| Nov 20, 2025 | 2.19 | 2.24 | 2.02 | 2.02 | 2.02 | 11,719,420 |
| Nov 19, 2025 | 2.12 | 2.20 | 2.09 | 2.14 | 2.14 | 7,749,994 |
| Nov 18, 2025 | 2.03 | 2.15 | 2.00 | 2.10 | 2.10 | 10,013,294 |
| Nov 17, 2025 | 2.08 | 2.10 | 2.00 | 2.03 | 2.03 | 9,408,512 |
| Nov 14, 2025 | 1.97 | 2.13 | 1.95 | 2.08 | 2.08 | 7,174,082 |
| Nov 13, 2025 | 2.03 | 2.06 | 1.97 | 2.00 | 2.00 | 9,234,032 |
| Nov 12, 2025 | 2.14 | 2.15 | 2.02 | 2.06 | 2.06 | 7,107,031 |
| Nov 11, 2025 | 2.15 | 2.16 | 2.08 | 2.14 | 2.14 | 6,534,737 |
| Nov 10, 2025 | 2.19 | 2.22 | 2.13 | 2.16 | 2.16 | 7,213,778 |
| Nov 7, 2025 | 2.08 | 2.14 | 2.00 | 2.13 | 2.13 | 10,641,820 |
| Nov 6, 2025 | 2.15 | 2.21 | 2.11 | 2.12 | 2.12 | 7,458,969 |
| Nov 5, 2025 | 2.19 | 2.27 | 2.06 | 2.15 | 2.15 | 13,359,911 |
| Nov 4, 2025 | 2.21 | 2.23 | 2.07 | 2.08 | 2.08 | 11,338,588 |
| Nov 3, 2025 | 2.40 | 2.40 | 2.25 | 2.26 | 2.26 | 9,025,332 |
| Oct 31, 2025 | 2.37 | 2.44 | 2.33 | 2.40 | 2.40 | 6,814,432 |
| Oct 30, 2025 | 2.38 | 2.44 | 2.35 | 2.36 | 2.36 | 7,761,601 |
| Oct 29, 2025 | 2.58 | 2.60 | 2.41 | 2.42 | 2.42 | 8,160,610 |
| Oct 28, 2025 | 2.65 | 2.66 | 2.57 | 2.58 | 2.58 | 7,604,884 |
| Oct 27, 2025 | 2.53 | 2.67 | 2.52 | 2.66 | 2.66 | 13,204,864 |
| Oct 24, 2025 | 2.45 | 2.51 | 2.42 | 2.47 | 2.47 | 10,620,307 |
| Oct 23, 2025 | 2.37 | 2.41 | 2.35 | 2.39 | 2.39 | 5,539,610 |
| Oct 22, 2025 | 2.42 | 2.45 | 2.30 | 2.36 | 2.36 | 12,031,358 |
| Oct 21, 2025 | 2.46 | 2.50 | 2.42 | 2.44 | 2.44 | 7,134,469 |
| Oct 20, 2025 | 2.41 | 2.49 | 2.41 | 2.45 | 2.45 | 6,673,996 |
| Oct 17, 2025 | 2.50 | 2.52 | 2.40 | 2.40 | 2.40 | 9,172,462 |
| Oct 16, 2025 | 2.60 | 2.67 | 2.51 | 2.53 | 2.53 | 10,106,506 |
| Oct 15, 2025 | 2.51 | 2.60 | 2.50 | 2.58 | 2.58 | 9,663,916 |
| Oct 14, 2025 | 2.43 | 2.58 | 2.38 | 2.51 | 2.51 | 9,593,757 |
| Oct 13, 2025 | 2.38 | 2.50 | 2.38 | 2.48 | 2.48 | 10,903,200 |
| Oct 10, 2025 | 2.46 | 2.48 | 2.36 | 2.36 | 2.36 | 12,035,394 |
| Oct 9, 2025 | 2.51 | 2.54 | 2.40 | 2.44 | 2.44 | 12,706,433 |
| Oct 8, 2025 | 2.52 | 2.61 | 2.50 | 2.53 | 2.53 | 9,234,738 |
| Oct 7, 2025 | 2.54 | 2.57 | 2.44 | 2.50 | 2.50 | 9,610,046 |
| Oct 6, 2025 | 2.55 | 2.60 | 2.52 | 2.53 | 2.53 | 8,059,668 |
| Oct 3, 2025 | 2.54 | 2.75 | 2.48 | 2.54 | 2.54 | 15,352,094 |
| Oct 2, 2025 | 2.50 | 2.52 | 2.42 | 2.50 | 2.50 | 7,698,904 |
| Oct 1, 2025 | 2.44 | 2.53 | 2.43 | 2.48 | 2.48 | 7,888,927 |
| Sep 30, 2025 | 2.57 | 2.57 | 2.41 | 2.46 | 2.46 | 8,083,502 |
| Sep 29, 2025 | 2.54 | 2.58 | 2.52 | 2.57 | 2.57 | 4,856,174 |
| Sep 26, 2025 | 2.44 | 2.55 | 2.44 | 2.54 | 2.54 | 5,809,005 |
| Sep 25, 2025 | 2.44 | 2.47 | 2.38 | 2.46 | 2.46 | 7,281,705 |
| Sep 24, 2025 | 2.59 | 2.65 | 2.50 | 2.50 | 2.50 | 6,214,914 |
| Sep 23, 2025 | 2.64 | 2.67 | 2.57 | 2.59 | 2.59 | 8,164,941 |
| Sep 22, 2025 | 2.72 | 2.73 | 2.62 | 2.67 | 2.67 | 9,046,285 |
Open, high, low and close are the prices as traded. Adjusted close accounts for splits and dividends, and is what the chart and returns use. Where a company changed its ticker, its history under the old symbol is included.
The Quiver API serves daily prices back to 2014 alongside congressional trades, insider trades, 13F holdings and lobbying, all under one key and inside Claude or ChatGPT through our MCP server.
Explore the Quiver APIWe estimate that -- received a compensation of -- in --, making them the highest paid executive at IBRX, per a recent SEC DEF 14A filing. We estimate that the median employee at ImmunityBio, Inc. is paid $183,848.
|
Name
|
Role
|
Salary
|
Bonus
|
Stock/Option Awards
|
Total Compensation
|
|---|